| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, January 2007, p. 283-296, Vol. 27, No. 1
0270-7306/07/$08.00+0 doi:10.1128/MCB.01282-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Pathology, Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611,1 Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina 27834,2 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160,3 Department of Medicine, Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri 631104
Received 13 July 2006/ Returned for modification 3 August 2006/ Accepted 17 October 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Every year over 1 million cases of nonmelanoma skin cancer are diagnosed in the United States alone, and chronic UV light exposure is widely believed to be the cause (20). Solar UV radiation reaching the earth's surface is a mixture of UVB and UVA, and it is generally believed that UVB irradiation plays a causative role in skin cancer (20). Multiple lines of evidence demonstrate that induction of COX-2 expression and the subsequent increase in prostaglandins contribute to skin cancer development. For example, transgenic mice overexpressing COX-2 in basal epidermal cells develop skin tumors (46), selective COX-2 inhibitors reduce UV-induced skin tumors in mice (17, 50), and mice that are deficient in COX-2 show a dramatic decrease in skin tumorigenesis (60).
COX-2 expression can be regulated through both transcriptional and posttranscriptional mechanisms. Although transcriptional activation of COX-2 is an early event in the initiation of tumorigenesis (31), abnormal posttranscriptional regulation also has been shown to play a central role in overexpression of the COX-2 protein during tumorigenesis (12). Posttranscriptional regulation of COX-2 expression is linked to the AU-rich element (ARE) within the 3'-untranslated region (3'-UTR) of COX-2 mRNA that controls both mRNA stability and protein translation (9). The ARE of the COX-2 gene is intact in healthy individuals (37) as well as in tumor cells (55), and numerous reports in the literature have demonstrated that dysregulation of posttranscriptional regulation by altered ARE-binding proteins is primarily responsible for enhanced expression of the COX-2 protein in many instances (13, 14, 45, 53). A number of trans-acting ARE-binding proteins have been identified thus far. Several of these proteins promote mRNA stability, such as HuR (16, 49) and hnRNP A1 (21), while others destabilize mRNA, such as AU-binding factor 1 (AUF1) (38, 66) and tristetraprolin (4, 39). Other proteins have been characterized that suppress protein translation, including T-cell-restricted intracellular antigen 1 (TIA-1) (13, 51) and TIA-1-related protein (TIAR) (19, 22, 65). In addition, ARE-binding protein CUGBP2 has been reported to increase COX-2 mRNA stability while simultaneously inhibiting its translation (45).
Although many of these ARE-binding proteins are located predominantly in the nucleus, they can shuttle between the nucleus and cytoplasm, and it is believed that their translocation to cytoplasm plays an important role in regulating the expression of target genes. For instance, the cytoplasmic localization of both HuR and TIAR increased under conditions of stress, and studies suggested that HuR associates with target mRNAs and transports these mRNAs from nucleus to cytoplasm, thus stabilizing them; TIAR recruits ARE-containing mRNAs into stress granules (SGs) to block their translation (28, 62).
Previous studies in our laboratory and others have shown that expression of COX-2 protein in keratinocytes is induced by UV light (1, 61a). We have further shown that this induction is blocked by treatment of UV-irradiated cells with the chemopreventive bioflavonoid apigenin, possibly through modulation of USF transcriptional activity (61a), and there are also reports that apigenin down-regulates COX-2 expression in macrophages (36, 52). Apigenin is a nonmutagenic, naturally occurring flavonoid found in a variety of fruits and leafy vegetables (10). A large body of evidence suggests that apigenin shows promise as a chemopreventive agent by stimulation of gap junctional and intercellular communication (6), inhibition of transformation and angiogenesis (18, 30), stabilization of wild-type p53 (42), and induction of cell cycle arrest (35). Topical application of apigenin in mice has been shown to reduce the number and size of tumors in the skin induced by both chemical carcinogens (63) and UV exposure (3).
In the present study, we investigated the role of apigenin in modulating posttranscriptional control of COX-2 expression in keratinocytes, since COX-2 mRNA contains typical ARE in the 3'-UTR. We demonstrated that apigenin enhanced COX-2 mRNA stability although it blocked the accumulation of UVB-induced steady-state mRNA at the same time. The mechanisms underlying COX-2 mRNA stabilization and protein translation were further examined, and we found that UVB treatment resulted in increased reporter gene activity through the 3'-UTR of COX-2 mRNA, which was prevented by apigenin. RNA-binding proteins HuR and TIAR bound COX-2 mRNA, and apigenin increased their localization in the cytoplasm. Reduction of HuR with small interfering RNA (siRNA) suppressed apigenin's ability to enhance COX-2 mRNA stability, whereas reduction of TIAR by siRNA reversed the ability of apigenin to inhibit UVB-induced COX-2 protein expression. Our results provide the first evidence that, in addition to transcriptional regulation, one of the mechanisms by which apigenin inhibits COX-2 expression is through suppression of translation by TIAR.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Western blot analysis. After treatment, cells were harvested at the indicated times in lysis buffer (20 mmol/liter Tris [pH 7.5], 150 mmol/liter NaCl, 2 mmol/liter EDTA, 10% glycerol, 1% Triton X-100, 1 mmol/liter phenylmethylsulfonyl fluoride, and protease inhibitor cocktail [Sigma]). Protein concentrations were determined by using the BCA reagent (Pierce, Rockford, IL), and proteins were resolved on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels followed by eletrophoretic transfer onto nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline-0.1% Tween 20 for 2 h and incubated at 4°C overnight with primary antibodies against COX-2 (C-20), HuR (3A2), TIAR (C-18), TIA-1 (C-20), actin (I-19), ß-tubulin (N-20), and hnRNP C1/C2 (N-16) (Santa Cruz Biotechnology, Santa Cruz, CA) and AUF1 (Upstate, Lake Placid, NY). Following incubation with appropriate horseradish peroxidase-conjugated secondary antibodies, signals were detected with an enhanced chemiluminescence system (Amersham Biosciences, Piscataway, NJ).
PGE2 measurement. Cells were grown in 12-well plates to near confluence. After treatment, cell-free culture media were collected and prostaglandin E2 (PGE2) levels were determined by competitive enzyme-linked immunosorbent assay (ELISA) as directed by the manufacturer (Cayman Chemical Co., Ann Arbor, MI). The production of PGE2 was normalized to protein concentrations.
Transient transfection. Firefly luciferase reporter gene constructs were generated as described previously by Morrison and coworkers (9). 308 cells were transiently transfected using Lipofectamine PLUS reagent (Invitrogen, Carlsbad, CA). Cells were plated in 24-well plates and grown to 80 to 90% confluence, and 0.2 µg reporter gene plasmid DNA and 1 ng control Renilla luciferase plasmid DNA (pRL-TK; Promega, Madison, WI) were prepared in 25 µl of serum-free medium and incubated with 4 µl of PLUS reagent at room temperature for 15 min, followed by 1 µl of Lipofectamine in an additional 25 µl serum-free medium. The mixture was incubated for another 15 min and layered onto the cells. After 3 h of incubation, normal medium containing 2x fetal bovine serum was added, and cells were incubated overnight for gene expression.
Luciferase assay. Luciferase activity was determined using the Dual-Luciferase reporter assay system (Promega) according to the manufacturer's protocol. Briefly, cells were rinsed with PBS and removed by scraping into 100 µl of passive lysis buffer. The lysate was then transferred into a tube and subjected to one or two freeze-thaw cycles to accomplish complete lysis of cells. Assays were performed by using a Monolight 3010 luminometer (Analytical Luminescence Laboratory, Ann Arbor, MI). Firefly luciferase activity is expressed as relative light units and was normalized to Renilla luciferase activity.
Real-time PCR assays.
Total RNA was
isolated at various times after treatment using TRIzol reagent
(Invitrogen) and treated with a DNA-free kit (Ambion, Austin, TX) to
eliminate genomic DNA contamination. RNA was reverse transcribed using
the SuperScript III first-strand synthesis system with random hexamer
primers (Invitrogen). After first-strand synthesis, for quantification
of COX-2 cDNA, real-time PCR was performed using the TaqMan Gene
Express assay (assay ID Mm00478374_m1; Applied Biosystems,
Foster City, CA) specific for the COX-2 gene. Fluorescence was detected
with an ABI Prism 7900HT real-time PCR system and normalized to rRNA as
measured using a TaqMan eukaryotic 18S rRNA endogenous control (Applied
Biosystems). Relative amounts of cDNA were calculated by the relative
quantification (
Ct) study method. For
quantification of luciferase cDNA, real-time PCR was performed using
luciferase gene-specific primers and the double-stranded DNA-binding
dye SYBR Green I as described previously
(9) and normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
content.
Cell fractionation. Cytoplasmic and nuclear cell fractions were prepared as described elsewhere (8) with modification. Cells were washed in ice-cold PBS, scraped into 200 µl of hypotonic buffer A (10 mmol/liter HEPES [pH 7.5], 10 mmol/liter KCl, 1 mmol/liter EDTA, 1 mmol/liter dithiothreitol [DTT], 1 mmol/liter MgCl2, 5% glycerol, 0.1 mmol/liter Na3VO4) supplemented with protease inhibitors as described above, incubated on ice for 10 min, and lysed by adding of 5 µl of buffer A containing 10% Nonidet P-40 (buffer B). Nuclei were isolated by centrifugation (1,500 x g for 10 min at 4°C). The supernatant was further centrifuged (16,000 x g for 5 min at 4°C) and saved as the cytoplasmic fraction. Nuclei were washed twice by centrifugation (1,500 x g for 10 min at 4°C) in buffer C (10 mmol/liter HEPES [pH 7.5], 10 mmol/liter KCl, 1 mmol/liter DTT, 1 mmol/liter MgCl2) and resuspended in nuclear lysis buffer D (20 mmol/liter HEPES [pH 7.5], 0.4 mol/liter NaCl, 1 mmol/liter EDTA, 1 mmol/liter DTT, 1 mmol/liter MgCl2, 25% glycerol, and protease inhibitors) on ice for 15 min with frequent vortexing. Lysed nuclei were centrifuged at 15,000 x g for 5 min at 4°C, and supernatant was saved as the nuclear fraction. For polysome separation, cell cytoplasmic fraction lysates were layered onto an ice-cold buffer (20 mmol/liter HEPES, pH 7.5, 50 mmol/liter KO-acetate, 5 mmol/liter MgO-acetate, 1 mmol/liter DTT, 100 U/ml RNase Out, and protease inhibitors) containing 30% sucrose. After ultracentrifugation at 100,000 x g for 2 h at 4°C in a Beckman SW55 Ti rotor, the supernatant was saved as the cytosolic fraction. The pellet was resuspended in buffer A containing 0.3 mol/liter NaCl, incubated on ice for 1 h, and centrifuged at 10,000 x g for 15 min at 4°C, and the resulting supernatant was saved as the polysomal fraction (40).
Immunofluorescence. Cells were cultured, treated, washed with PBS, and fixed for 30 min in PBS containing 4% paraformaldehyde at room temperature. Cell preparations were washed with PBS again and incubated in PBS containing 0.1% Triton X-100 for 10 min. After incubation in blocking buffer (PBS containing 0.1% Tween 20, 3% bovine serum albumin, and 3% donkey serum) for 1 h, the slides were incubated with either goat anti-TIAR or mouse anti-HuR antibody (Santa Cruz Biotechnology) in PBS containing 3% donkey serum for 48 h at 4°C, washed with PBS containing 0.1% Tween 20, and further incubated with Alexa Fluor 594 donkey anti-goat immunoglobulin G (IgG) or Alexa Fluor 594 donkey anti-mouse IgG (Invitrogen) for 2 h in the dark. After a final wash with PBS, the slides were mounted in Vectashield with diamidinophenylindole (Vector Laboratories) and visualized with a Zeiss Axiovert 200 (Carl Zeiss MicroImaging, Inc.) fluorescence microscope.
Immunoprecipitation of mRNP complex and reverse transcription-PCR (RT-PCR). Cytoplasmic extracts (400 µg, harvested as described above except adding 100 U/ml RNase Out [Invitrogen] in buffer A) were mixed with 15 µg of HuR, TIAR, or normal mouse IgG antibody. After incubation on ice for 2 h, 30 µl protein A/G Plus-agarose beads (Santa Cruz Biotechnology) was added to each sample, followed by mixture for a further 1.5 h at 4°C. Samples were centrifuged at 2,000 x g for 2 min at 4°C, the pelleted beads were washed four times with cold buffer A supplemented with protease and RNase inhibitors, and RNA was isolated using the TRIzol reagent. DNase I treatment and reverse transcription were performed as described above. The cDNA was used as template for PCR (30 s at 94°C, 30 s at 56°C, and 1 min at 72°C, for 35 cycles) with COX-2-specific primers (forward, 5'-GCTGTACAAGCAGTGGCAAA-3'; reverse, 5'-CCCCAAAGATAGCATCTGGA-3') and ß-actin-specific primers (forward, 5'-TATGGAATCCTGTGGCATCC-3'; reverse, 5'-GTACTTGCGCTCAGGAGGAG-3'). These primers produce amplicons that span different introns, allowing the discrimination of cDNA- and genomic DNA-related amplification. PCR products were visualized by using an ethidium bromide-stained 1.2% agarose gel.
RNA interference experiment. For TIAR knockdown, 308 cells were transfected by using Lipofectamine PLUS (Invitrogen) with pSM2-TIAR-shRNA plasmid (RMM1766-96883937; Open Biosystems, Huntsville, AL), which contains a short hairpin RNA (shRNA) sequence targeting mouse TIAR mRNA. After 48 h of incubation, cells were treated with puromycin (2 µg/ml; Sigma), single clones of puromycin-resistant cells were selected, and TIAR expression was examined by immunoblotting. Clones with the highest knockdown were used for subsequent experiments. An shRNA nonsilencing control vector (Open Biosystems) was used as a control. The control vector contains nonsilencing shRNA sequence that has no homology to any known mammalian genes. For HuR knockdown, siRNA duplex targeting mouse HuR mRNA and nontargeting control siRNA (Santa Cruz Biotechnology) were used. The transfection of siRNA into 308 cells was performed by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions, and 48 h after transfection, cell density was adjusted so that cell confluence would be 90% after the transfected cells were kept in culture for another 48 h.
Analysis of nascent COX-2 protein. For metabolic labeling, 308 cells were incubated for 1 h in Dulbecco's modified Eagle's medium without methionine and cysteine (Sigma) before treatment (UVB irradiation or UVB plus apigenin). At 8 h posttreatment, each sample was labeled with 500 µCi L-[35S]methionine and L-[35S]cysteine (GE Healthcare, Piscataway, NJ) for 20 min, cells were harvested in lysis buffer, and immunoprecipitations were carried out overnight at 4°C using COX-2 antibody or normal goat IgG. Following extensive washes in washing buffer (50 mmol/liter Tris-HCl [pH 7.5], 250 mmol/liter NaCl, 5 mmol/liter EDTA, and 0.5% NP-40), the immunoprecipitated materials were resolved by SDS-polyacrylamide gel electrophoresis and assessed by autoradiography.
| RESULTS |
|---|
|
|
|---|
]anthracene, contains a point-mutated Ha-ras gene
and a wild-type p53 gene
(56). COX-2 protein
expression was examined in cells irradiated with UVB at various doses,
and Western blot analysis demonstrated that UVB induced COX-2 protein
expression dramatically, with a peak at doses from 750 to 1,000
J/m2 (Fig.
1A). To further determine the time of maximal COX-2 protein induction, cells
were irradiated with 1,000 J/m2 UVB and harvested at
different time points. The increase of COX-2 protein expression
occurred rapidly after irradiation, with an approximately 10-fold
maximal increase at 8 h after treatment. This level of COX-2
protein expression was sustained for more than 18 h
postirradiation (Fig. 1B).
Two COX-2 bands were detected in the Western blot analysis. The lower
band (72 kDa) corresponds to COX-2 that is N-glycosylated at three
sites, while the upper band (74 kDa) was identified as corresponding to
the COX-2 form that is N-glycosylated at four sites, as reported
previously (48) and
confirmed by disappearance of the upper band after treatment with the
glycosylation inhibitor tunicamycin (data not shown).
|
In view of the fact that apigenin treatment inhibited UVB-induced COX-2 protein levels, we next determined the effect of apigenin treatment on PGE2, a downstream product of COX-2. PGE2 levels were measured by ELISA in cell culture medium after cells were treated with UVB, apigenin, or UVB plus apigenin. Consistent with the observed increase of COX-2 expression induced by UVB and inhibition of COX-2 expression by apigenin, we found that DMSO (as vehicle) or apigenin-treated cells produced little PGE2 (Fig. 1D). In contrast, cells exposed to UVB were shown to have a 10-fold increase in PGE2 that was reduced to even less than the basal level by adding apigenin (Fig. 1D). Overall, these results demonstrated that apigenin not only suppresses UVB-induced COX-2 protein expression but also inhibits the level of its downstream product, PGE2.
UVB irradiation and apigenin treatment stabilize COX-2 mRNA. To further investigate the mechanism responsible for the inhibitory effect of apigenin on COX-2 expression, we examined the steady-state levels of COX-2 mRNA by real-time RT-PCR assay. Total RNAs were purified from cells that had been treated with UVB, apigenin, or UVB plus apigenin and harvested at different times posttreatment. As shown in Fig. 2, UVB induced a dramatic increase in COX-2 mRNA levels and apigenin significantly decreased the levels of COX-2 mRNA in both UVB- and sham-irradiated cells. The concentration of mRNA is determined by rates of both synthesis and degradation, and previous studies in our laboratory have demonstrated that UVB exposure induces COX-2 expression by transcriptional up-regulation of the COX-2 promoter and apigenin blocks this induction through modulation of USF transcriptional activity (61a). In the present report, we further investigated whether message stabilization/destabilization and modulation of protein translation could play a role in apigenin-mediated inhibition of COX-2 expression, because COX-2 mRNA contains typical ARE in the 3'-UTR and there is growing evidence that the ARE within the 3'-UTR of COX-2 mRNA can affect both mRNA stability and protein translation (9).
|
|
60%. The ARE region nt 1 to 60 or the ARE deleted from the
full-length 3'-UTR (nt 60 to 2232) also reduced reporter
activity
40% and
50%, respectively. These results
suggested that the 60-bp ARE region was responsible for altering
reporter gene expression and that additional cis-elements (not
exclusively those in the nt 1 to 60 ARE region) are present that alter
message stability and translation efficiency as reported previously
(9). However, when we
examined the effects of UVB irradiation on the luciferase activity of
each of these constructs in 308 cells, we found that UVB increased
luciferase activity by
30% and
40% in the case of the
full-length 3'-UTR (nt 1 to 2232) and the ARE region (nt 1 to
60), respectively, whereas the ARE deleted from the full-length
3'-UTR (nt 60 to 2232) appeared to be unresponsive to UVB (Fig.
4B). When apigenin
treatment was combined with UVB exposure, it suppressed the effect of
UVB on luciferase reporter gene expression (Fig.
4B). Taken together, these
results suggested that the nt 1 to 60 ARE region of COX-2 mRNA is
important for both UVB response and apigenin inhibition.
|
Apigenin increases levels of HuR and TIAR in the cytoplasm. Posttranscription regulation mediated by AREs is primarily governed by RNA-binding proteins (RBPs) that bind to mRNAs containing ARE and ensure their proper processing and export, as well as subcytoplasmic transit, stability, and translation rate (11, 15). Among these RBPs, three ARE-RBPs (HuR, TIA-1, and TIAR) have been confirmed to influence translation, and numerous reports have demonstrated that cytoplasmic localization is associated with their functional activity (22, 40, 51). Therefore, it was our primary interest to examine the subcellular localization of HuR, TIA-1, and TIAR under conditions in which COX-2 expression is induced by UVB and inhibited by apigenin. Western blot analysis using whole-cell lysates demonstrated that there was no change in total HuR, TIA-1, and TIAR expression during UVB and apigenin treatment of 308 cells (Fig. 5A). When subcellular fractions were further analyzed, we observed a higher level of cytoplasmic HuR and TIAR in apigenin-treated and UVB plus apigenin-treated cells, but not in control or UVB-irradiated cells (Fig. 5B). Verification that nuclear proteins did not leak into the cytoplasmic fractions during the fractionation process was obtained by immunoblotting the same membranes to detect the nuclear marker hnRNP C1/C2 protein. hnRNP C1/C2 protein was found only in the nuclear fraction, while the cytoplasmic marker ß-tubulin was detected only in the cytoplasmic fraction (Fig. 5B). TIA-1 and another RNA-binding protein AUF1 were also examined, and they were exclusively located in the nucleus irrespective of culture treatment (Fig. 5B).
|
HuR and TIAR bind endogenous COX-2 mRNA in 308 cells. The fact that both HuR and TIAR increased their localization to the cytoplasm under apigenin treatment suggested the possibility that they may be responsible for suppression of COX-2 expression by apigenin. To investigate the endogenous association between these RNA-binding proteins and COX-2 mRNA in 308 cells, we used an immunoprecipitation assay followed by measurement of COX-2 mRNA by RT-PCR. As shown in Fig. 6A, HuR and TIAR coimmunoprecipitated with COX-2 mRNA in a UVB-dependent manner when using anti-HuR and anti-TIAR antibodies (lanes 7 and 11, respectively, for UVB-treated cells, and lanes 9 and 13, respectively, for UVB plus apigenin treatment). Control samples treated with normal IgG showed only very weak amplification, and no amplification was observed in the absence of antibody (beads only). Lane 18 is a positive control to confirm the amplification from COX-2 cDNA plasmid. Based on the size of all amplicons, there is no genomic contamination, because the PCR product would be much larger if the intron sequence were amplified as well. The levels of the housekeeping ß-actin mRNA were also examined as a sample input control. Since treatment of cells with UVB, UVB plus apigenin, or apigenin alone resulted in a dramatic change of steady-state COX-2 mRNA levels (Fig. 2), the levels of COX-2 mRNA were monitored in parallel samples by real-time PCR (Fig. 6B); UVB treatment increased the steady-state level of COX-2 mRNA dramatically, and apigenin treatment down-regulated the steady-state level of COX-2 mRNA to the same level as that in untreated cells. Taken together, we propose that the increase of HuR- and TIAR-bound COX-2 mRNA after UVB treatment (lanes 7 and 11, respectively) is due to the increased expression of COX-2 mRNA induced by UVB, since we did not observe an increase in cytoplasmic HuR and TIAR following UVB treatment.(Fig. 5B). In contrast we propose that the increase of HuR- and TIAR-bound COX-2 mRNA after UVB plus apigenin treatment (Fig. 6A, lanes 9 and 13, respectively) is due to markedly increased levels of cytoplasmic HuR and TIAR in UVB plus apigenin-treated cells (Fig. 5B), since the level of COX-2 mRNA was nearly the same in UVB plus apigenin-treated cells as in untreated cells (Fig. 6B). Overall, these date provide definitive evidence that HuR and TIAR bind COX-2 mRNA in 308 keratinocyte cells.
|
|
30% of the amount of the nonsilencing control. Our results
further demonstrated that reduction of TIAR protein levels resulted in
a blockade of apigenin's inhibitory effect on UVB-induced COX-2 protein
expression, with approximately twofold-greater COX-2 protein expression
in apigenin-treated cells under TIAR knockdown than in cells
transfected with control siRNA (Fig.
8A). Quantitative analysis
showed the change was significant, with a P value of
<0.05 (Fig. 8B).
Given the extensive sequence homology between TIAR and TIA-1, we also
examined the levels of TIA-1 in the TIAR knockdown cells and
demonstrated that TIA-1 levels remained unchanged (Fig.
8A), verifying the
specificity of TIAR knockdown. As determined by real-time RT-PCR
analysis, TIAR knockdown did not significantly alter COX-2 mRNA levels
in untreated or UVB-treated cells, but cells treated with UVB plus
apigenin showed significant reduction in COX-2 mRNA level when TIAR was
knocked down (Fig. 8C). We
next performed biosynthetic labeling studies with
[35S]methionine-cysteine to measure nascent translation of
COX-2 protein. In keeping with TIAR's role as a translation silencer,
our results showed that TIAR knockdown partially rescued the
apigenin-mediated translational suppression of COX-2 protein in
UVB-treated cells (Fig.
8D). Together, these
results confirmed our hypothesis that one of the mechanisms by which
apigenin treatment results in inhibition of COX-2 expression is through
mediating TIAR suppression of protein
translation.
|
| DISCUSSION |
|---|
|
|
|---|
TIAR has been reported to participate in the regulation of alternative pre-mRNA splicing (34) and promote apoptosis (58). However, TIAR has been best characterized as a silencer of translation (19, 32, 41, 65). It was cloned based on similarity to TIA-1 (another suppressor of translation through binding target ARE-bearing mRNAs), and the two proteins share 80% amino acid identity (26). Like TIA-1, TIAR is normally localized in the nucleus and translocated to the cytoplasm under stress conditions, and it has also been shown to bind the ARE of COX-2 mRNA in vitro (7). Unlike TIA-1/ mice, however, the TIAR/ mouse is highly embryonic lethal (2), and so the exact role of TIAR in COX-2 expression has not been firmly established. In this study, we demonstrated that TIAR associates with endogenous COX-2 mRNA by using an immunoprecipitation-RT-PCR assay, and we further showed that knockdown of TIAR reversed apigenin's ability to inhibit UVB-induced COX-2 protein expression and knockdown of TIAR enhanced nascent COX-2 translation, thus providing the first evidence that TIAR functionally inhibits COX-2 protein expression by modulating translation.
It should be pointed out that RNA-binding protein CUGBP2 itself can increase COX-2 mRNA stability while simultaneously inhibiting its translation, and this function is dependent on CUGBP32's binding to the COX-2 ARE and translocation from the nucleus to cytoplasm (45). However, unlike HuR or TIAR, we did not detect any change in expression of CUGB2 in whole-cell extracts or cytoplasm under UVB or apigenin treatment (data not shown), indicating this protein may not be responsible for the inhibition of COX-2 expression by apigenin in 308 cells. Meanwhile, recent reports have shown that RBPs can influence their targets without changes in abundance themselves (25, 41); thus additional studies may be needed to address the role of CUGBP32 in regulation of COX-2 expression by UVB/apigenin.
Previous reports demonstrated that UVC increases p21 mRNA stability and promotes p53 expression through increasing localization of HuR in cytoplasm (40, 62). In the present study, UVB also enhanced COX-2 mRNA stability. However, we did not observe an increase in the HuR level in the cytoplasm after UVB irradiation alone (Fig. 5), and reduced HuR had no effect on UVB-induced COX-2 protein expression and message stability (Fig. 7). These findings indicate that there may be another RNA-binding protein(s) that is required for UVB-induced COX-2 expression. Alternatively, it is possible that the dramatic UVB-induced COX-2 protein expression seen in Fig. 1 is mainly the result of increased transcription, rather than substantial modulation at the 3' end, as reflected by the relatively modest effects of the 3'-UTR on luciferase reporter activity in cells treated with UVB alone.
Although studies have predominantly demonstrated that cytoplasmic HuR can stabilize mRNA by binding to AREs within the 3'-UTR of specific mRNAs and thus enhance protein expression (53, 57), growing evidence indicates that HuR's functions are not definite. For example, HuR binds the 5'-UTR of insulin-like growth factor I receptor or p27 to inhibit translation (29, 43), binds the 3'-UTR of p53 to enhance translation (40), synergizes with TIA-1 to stabilize TNF mRNA but inhibits protein translation (23), and coordinates with TIA-1 to regulate cytochrome c translation (25). Here, we show that HuR stabilizes COX-2 mRNA but TIAR works downstream to suppress protein translation, indicating that the final effect of HuR's function not only is dependent on the cis-elements of target mRNA that it binds but also is regulated by other molecules that work together with HuR.
The fact that both HuR and TIAR bound COX-2 mRNA and increased their cytoplasmic localization after apigenin treatment suggested that they may be functionally linked through association each other or association with common target mRNA. To test these possibilities, we employed protein coimmunoprecipitation techniques, but we found that HuR and TIAR did not bind each other through protein-protein interactions (data not shown), and so it is possible that they are just functionally linked through association with COX-2 mRNA in the current system. Although antibody supershift-electrophoretic mobility shift assay results show that HuR and TIAR associate with the same ARE of COX-2 (7), at present, we do not know whether they bind the COX-2 mRNA simultaneously or sequentially. Polysomal/cytosolic distribution (Fig. 5D) showed that TIAR was almost exclusively found in the cytosol, which is consistent with its function as a translation repressor. In contrast, HuR was found mainly located in the polysomal fraction as reported previously (33). Apigenin treatment or apigenin plus UVB treatment increased the HuR levels at both the polysome and cytosol, which also reflects the multifunctions of HuR's influence on target mRNA stability or translation.
As mentioned above, COX-2 overexpression plays an important role in carcinogenesis. While chemotherapy is a main approach to treat cancer, many chemotherapeutic agents, such as taxanes, induce COX-2 expression (44), raising the possibility that inhibiting COX-2 will greatly augment the anticancer effect of chemotherapy if the agents are coadministered with a selective COX-2 inhibitor. However, the gastrointestinal toxicity of nonsteroidal antiinflammatory drugs and the recent findings that selective COX-2 inhibitors can produce potentially adverse side effects on the cardiovascular system (61) may reduce the enthusiasm for using them as cancer chemopreventive agents. Here, we demonstrate that apigenin, a diet-derived agent, can inhibit inducible COX-2 expression by either modulating transcription or suppressing protein translation. Meanwhile, apigenin at up to 100 µmol/liter does not affect COX-2 enzyme activity and has no effect on constitutive COX-1 expression (J. Pelling, A. Abu-Yousif, et al., unpublished data), thus providing an attractive alternative for chemoprevention and chemotherapy.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Published ahead of print on 30 October 2006. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Beck,
A. R., I. J. Miller, P. Anderson, and M.
Streuli. 1998. RNA-binding protein TIAR is essential
for primordial germ cell development. Proc. Natl. Acad. Sci.
USA
95:2331-2336.
3. Birt, D. F., D. Mitchell, B. Gold, P. Pour, and H. C. Pinch. 1997. Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid.Anticancer Res. 17:85-91.[Medline]
4. Carballo,
E., W. S. Lai, and P. J. Blackshear.1998
. Feedback inhibition of macrophage tumor necrosis
factor-alpha production by tristetraprolin. Science
281:1001-1005.
5. Chan,
G., J. O. Boyle, E. K. Yang, F. Zhang, P.
G. Sacks, J. P. Shah, D. Edelstein, R. A. Soslow,
A. T. Koki, B. M. Woerner, J. L.
Masferrer, and A. J. Dannenberg.1999
. Cyclooxygenase-2 expression is up-regulated in
squamous cell carcinoma of the head and neck. Cancer
Res.
59:991-994.
6. Chaumontet, C., C. Droumaguet, V. Bex, C. Heberden, I. Gaillard-Sanchez, and P. Martel. 1997. Flavonoids (apigenin, tangeretin) counteract tumor promoter-induced inhibition of intercellular communication of rat liver epithelial cells. Cancer Lett. 114:207-210.[CrossRef][Medline]
7. Cok,
S. J., S. J. Acton, and A. R.
Morrison. 2003. The proximal region of the
3'-untranslated region of cyclooxygenase-2 is recognized by a
multimeric protein complex containing HuR, TIA-1, TIAR, and the
heterogeneous nuclear ribonucleoprotein U. J. Biol.
Chem.
278:36157-36162.
8. Cok,
S. J., S. J. Acton, A. E. Sexton, and
A. R. Morrison. 2004. Identification of
RNA-binding proteins in RAW 264.7 cells that recognize a
lipopolysaccharide-responsive element in the 3'-untranslated
region of the murine cyclooxygenase-2 mRNA. J. Biol.
Chem.
279:8196-8205.
9. Cok,
S. J., and A. R. Morrison. 2001.
The 3'-untranslated region of murine cyclooxygenase-2 contains
multiple regulatory elements that alter message stability and
translational efficiency. J. Biol. Chem.
276:23179-23185.
10. Czeczot, H., B. Tudek, J. Kusztelak, T. Szymczyk, B. Dobrowolska, G. Glinkowska, J. Malinowski, and H. Strzelecka. 1990. Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat. Res. 240:209-216.[CrossRef][Medline]
11. Derrigo, M., A. Cestelli, G. Savettieri, and I. Di Liegro.2000 . RNA-protein interactions in the control of stability and localization of messenger RNA. Int. J. Mol. Med. 5:111-123.[Medline]
12. Dixon, D. A. 2004. Dysregulated post-transcriptional control of COX-2 gene expression in cancer.Curr. Pharm. Des. 10:635-646.[CrossRef][Medline]
13. Dixon,
D. A., G. C. Balch, N. Kedersha, P. Anderson,
G. A. Zimmerman, R. D. Beauchamp, and S.
M. Prescott. 2003. Regulation of cyclooxygenase-2
expression by the translational silencer TIA-1. J. Exp.
Med.
198:475-481.
14. Dixon, D. A., N. D. Tolley, P. H. King, L. B. Nabors, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott. 2001. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Investig. 108:1657-1665.[CrossRef][Medline]
15. Dreyfuss, G., V. N. Kim, and N. Kataoka. 2002. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 3:195-205.[CrossRef][Medline]
16. Fan, X. C., and J. A. Steitz. 1998. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17:3448-3460.[CrossRef][Medline]
17. Fischer,
S. M., C. J. Conti, J. Viner, C. M.
Aldaz, and R. A. Lubet. 2003. Celecoxib and
difluoromethylornithine in combination have strong therapeutic activity
against UV-induced skin tumors in mice. Carcinogenesis
24:945-952.
18. Fotsis,
T., M. S. Pepper, E. Aktas, S. Breit, S. Rasku, H.
Adlercreutz, K. Wahala, R. Montesano, and L. Schweigerer.1997
. Flavonoids, dietary-derived
inhibitors of cell proliferation and in vitro angiogenesis.Cancer Res.
57:2916-2921.
19. Gueydan,
C., L. Droogmans, P. Chalon, G. Huez, D. Caput, and V. Kruys.1999
. Identification of TIAR as a protein binding to the
translational regulatory AU-rich element of tumor necrosis factor alpha
mRNA. J. Biol. Chem.
274:2322-2326.
20. Hall, E. J., M. Astor, J. Bedford, C. Borek, S. B. Curtis, M. Fry, C. Geard, T. Hei, J. Mitchell, N. Oleinick, et al.1988 . Basic radiobiology. Am. J. Clin. Oncol. 11:220-252.[Medline]
21. Hamilton,
B. J., C. M. Burns, R. C. Nichols, and
W. F. Rigby. 1997. Modulation of AUUUA
response element binding by heterogeneous nuclear ribonucleoprotein A1
in human T lymphocytes. The roles of cytoplasmic location,
transcription, and phosphorylation. J. Biol.
Chem.
272:28732-28741.
22. Kandasamy,
K., K. Joseph, K. Subramaniam, J. R. Raymond, and
B. G. Tholanikunnel. 2005. Translational
control of ß2-adrenergic receptor mRNA by T-cell-restricted
intracellular antigen-related protein. J. Biol.
Chem.
280:1931-1943.
23. Katsanou, V., O. Papadaki, S. Milatos, P. J. Blackshear, P. Anderson, G. Kollias, and D. L. Kontoyiannis. 2005. HuR as a negative posttranscriptional modulator in inflammation.Mol. Cell 19:777-789.[CrossRef][Medline]
24. Kawai,
T., J. Fan, K. Mazan-Mamczarz, and M. Gorospe. 2004.
Global mRNA stabilization preferentially linked to translational
repression during the endoplasmic reticulum stress response.Mol. Cell. Biol.
24:6773-6787.
25. Kawai,
T., A. Lal, X. Yang, S. Galban, K. Mazan-Mamczarz, and M.
Gorospe. 2006. Translational control of
cytochrome c by RNA-binding proteins TIA-1 and HuR.Mol. Cell. Biol.
26:3295-3307.
26. Kawakami,
A., Q. Tian, X. Duan, M. Streuli, S. F. Schlossman, and P.
Anderson. 1992. Identification and functional
characterization of a TIA-1-related nucleolysin. Proc. Natl.
Acad. Sci. USA
89:8681-8685.
27. Kawamori,
T., C. V. Rao, K. Seibert, and B. S. Reddy.1998
. Chemopreventive activity of celecoxib, a specific
cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer
Res.
58:409-412.
28. Kedersha, N., and P. Anderson. 2002. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability.Biochem. Soc. Trans. 30:963-969.[CrossRef][Medline]
29. Kullmann,
M., U. Gopfert, B. Siewe, and L. Hengst. 2002. ELAV/Hu
proteins inhibit p27 translation via an IRES element in the p27
5'UTR. Genes Dev.
16:3087-3099.
30. Kuo, M. L., and N. C. Yang. 1995. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem. Biophys. Res. Commun. 212:767-775.[CrossRef][Medline]
31. Kutchera,
W., D. A. Jones, N. Matsunami, J. Groden, T. M.
McIntyre, G. A. Zimmerman, R. L. White, and
S. M. Prescott. 1996. Prostaglandin H
synthase 2 is expressed abnormally in human colon cancer: evidence for
a transcriptional effect. Proc. Natl. Acad. Sci. USA
93:4816-4820.
32. Lal,
A., K. Abdelmohsen, R. Pullmann, T. Kawai, S. Galban, X. Yang,
G. Brewer, and M. Gorospe. 2006.
Posttranscriptional derepression of GADD45
by genotoxic
stress. Mol. Cell
22:117-128.[CrossRef][Medline]
33. Lal, A., K. Mazan-Mamczarz, T. Kawai, X. Yang, J. L. Martindale, and M. Gorospe. 2004. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 23:3092-3102.[CrossRef][Medline]
34. Le
Guiner, C., F. Lejeune, D. Galiana, L. Kister, R. Breathnach, J.
Stevenin, and F. Del Gatto-Konczak. 2001. TIA-1 and
TIAR activate splicing of alternative exons with weak 5' splice
sites followed by a U-rich stretch on their own pre-mRNAs.J. Biol. Chem.
276:40638-40646.
35. Lepley, D. M., and J. C. Pelling. 1997. Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol. Carcinog. 19:74-82.[CrossRef][Medline]
36. Liang,
Y. C., Y. T. Huang, S. H. Tsai,
S. Y. Lin-Shiau, C. F. Chen, and J. K.
Lin. 1999. Suppression of inducible cyclooxygenase and
inducible nitric oxide synthase by apigenin and related flavonoids in
mouse macrophages. Carcinogenesis
20:1945-1952.
37. Lin,
H. J., K. M. Lakkides, T. O. Keku,
S. T. Reddy, A. D. Louie, I. H. Kau, H.
Zhou, J. S. Gim, H. L. Ma, C. F.
Matthies, A. Dai, H. F. Huang, A. M. Materi,
J. H. Lin, H. D. Frankl, E. R. Lee,
S. I. Hardy, H. R. Herschman, B. E.
Henderson, L. N. Kolonel, L. Le Marchand, R. M.
Garavito, R. S. Sandler, R. W. Haile, and
W. L. Smith. 2002. Prostaglandin H synthase
2 variant (Val511Ala) in African Americans may reduce the risk for
colorectal neoplasia. Cancer Epidemiol. Biomarkers Prev.
11:1305-1315.
38. Loflin,
P., C. Y. Chen, and A. B. Shyu.1999
. Unraveling a cytoplasmic role for hnRNP D in the in
vivo mRNA destabilization directed by the AU-rich element. Genes
Dev.
13:1884-1897.
39. Mahtani,
K. R., M. Brook, J. L. Dean, G. Sully, J.
Saklatvala, and A. R. Clark. 2001.
Mitogen-activated protein kinase p38 controls the expression and
posttranslational modification of tristetraprolin, a regulator of tumor
necrosis factor alpha mRNA stability. Mol. Cell. Biol.
21:6461-6469.
40. Mazan-Mamczarz,
K., S. Galban, I. Lopez de Silanes, J. L. Martindale, U.
Atasoy, J. D. Keene, and M. Gorospe. 2003.
RNA-binding protein HuR enhances p53 translation in response to
ultraviolet light irradiation. Proc. Natl. Acad. Sci.
USA
100:8354-8359.
41. Mazan-Mamczarz,
K., A. Lal, J. L. Martindale, T. Kawai, and M. Gorospe.2006
. Translational repression by RNA-binding protein
TIAR. Mol. Cell. Biol.
26:2716-2727.
42. McVean,
M., H. Xiao, K. Isobe, and J. C. Pelling.2000
. Increase in wild-type p53 stability and
transactivational activity by the chemopreventive agent apigenin in
keratinocytes. Carcinogenesis.
21:633-639.
43. Meng,
Z., P. H. King, L. B. Nabors, N. L.
Jackson, C. Y. Chen, P. D. Emanuel, and
S. W. Blume. 2005. The ELAV RNA-stability
factor HuR binds the 5'-untranslated region of the human IGF-IR
transcript and differentially represses cap-dependent and IRES-mediated
translation. Nucleic Acids Res.
33:2962-2979.
44. Moos,
P. J., D. T. Muskardin, and F. A.
Fitzpatrick. 1999. Effect of taxol and taxotere on
gene expression in macrophages: induction of the prostaglandin H
synthase-2 isoenzyme. J. Immunol.
162:467-473.
45. Mukhopadhyay, D., C. W. Houchen, S. Kennedy, B. K. Dieckgraefe, and S. Anant. 2003. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol. Cell 11:113-126.[CrossRef][Medline]
46. Muller-Decker,
K., G. Neufang, I. Berger, M. Neumann, F. Marks, and G.
Furstenberger. 2002. Transgenic cyclooxygenase-2
overexpression sensitizes mouse skin for carcinogenesis. Proc.
Natl. Acad. Sci. USA
99:12483-12488.
47. Oshima,
M., J. E. Dinchuk, S. L. Kargman, H. Oshima, B.
Hancock, E. Kwong, J. M. Trzaskos, J. F. Evans, and
M. M. Taketo. 1996. Suppression of
intestinal polyposis in Apc
716 knockout mice by inhibition of
cyclooxygenase 2 (COX-2). Cell
87:803-809.[CrossRef][Medline]
48. Otto,
J. C., D. L. DeWitt, and W. L. Smith.1993
. N-glycosylation of prostaglandin endoperoxide
synthases-1 and -2 and their orientations in the endoplasmic reticulum.J. Biol. Chem.
268:18234-18242.
49. Peng, S. S., C. Y. Chen, N. Xu, and A. B. Shyu. 1998. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J. 17:3461-3470.[CrossRef][Medline]
50. Pentland,
A. P., J. W. Schoggins, G. A. Scott,
K. N. Khan, and R. Han. 1999. Reduction of
UV-induced skin tumors in hairless mice by selective COX-2 inhibition.Carcinogenesis
20:1939-1944.
51. Piecyk, M., S. Wax, A. R. Beck, N. Kedersha, M. Gupta, B. Maritim, S. Chen, C. Gueydan, V. Kruys, M. Streuli, and P. Anderson.2000 . TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J. 19:4154-4163.[CrossRef][Medline]
52. Raso, G. M., R. Meli, G. Di Carlo, M. Pacilio, and R. Di Carlo.2001 . Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci. 68:921-931.[CrossRef][Medline]
53. Sengupta,
S., B. C. Jang, M. T. Wu, J. H. Paik, H.
Furneaux, and T. Hla. 2003. The RNA-binding protein
HuR regulates the expression of cyclooxygenase-2. J.
Biol. Chem.
278:25227-25233.
54. Smith,
W. L., R. M. Garavito, and D. L.
DeWitt. 1996. Prostaglandin endoperoxide H synthases
(cyclooxygenases)-1 and -2. J. Biol. Chem.
271:33157-33160.
55. Spirio,
L. N., D. A. Dixon, J. Robertson, M. Robertson, J.
Barrows, E. Traer, R. W. Burt, M. F. Leppert, R.
White, and S. M. Prescott. 1998. The
inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not
mutated in patients with attenuated adenomatous polyposis coli.Cancer Res.
58:4909-4912.
56. Strickland,
J. E., D. A. Greenhalgh, A. Koceva-Chyla, H.
Hennings, C. Restrepo, M. Balaschak, and S. H. Yuspa.1988
. Development of murine epidermal cell lines which
contain an activated ras Ha oncogene and form papillomas in skin grafts
on athymic nude mouse hosts. Cancer Res.
48:165-169.
57. Subbaramaiah, K., T. P. Marmo, D. A. Dixon, and A. J. Dannenberg. 2003. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involve